AngioDynamics, Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended May 31, 2017. Although the request references 2016 Q4, this filing is an annual report and includes quarterly results; it is not a standalone 2016 Q4 filing.
Business context
AngioDynamics designs, manufactures and sells medical devices used mainly in minimally invasive procedures across Peripheral Vascular, Vascular Access and Oncology/Surgery. It sells in the U.S. primarily through a direct sales force and internationally through direct sales and distributors. International sales were 19% of FY2017 revenue.
Financial performance
| Metric | FY2017 | FY2016 |
|---|---|---|
| Net sales | $349.6 million | $353.9 million |
| Gross profit / margin | $176.2 million / 50.4% | $174.3 million / 49.3% |
| Operating income | $13.0 million | $1.0 million |
| Net income (loss) | $5.0 million | $(43.6) million |
| Diluted EPS | $0.14 | $(1.21) |
| Cash from operating activities | $55.7 million | $45.2 million |
| Cash and marketable securities | $48.8 million | $34.0 million |
| Working capital | $82.4 million | $79.5 million |
| Debt outstanding | $97.5 million | $120.5 million |
FY2017 operating margin was approximately 3.7% and net margin approximately 1.4%. Net cash increased $15.2 million during the year. Management said available cash, operating cash generation and access to the revolving facility should cover anticipated needs for at least 12 months. The company reported net debt to Credit Agreement-defined Consolidated EBITDA of 1.4x and compliance with its debt covenants.
Changes versus FY2016
- Revenue declined 1% (approximately 1.2% based on reported amounts); constant-currency revenue also declined 1%.
- Peripheral Vascular revenue rose 1% to $208.6 million; Vascular Access fell 3% to $96.5 million; Oncology/Surgery fell 9% to $44.6 million.
- Gross margin improved 1.1 percentage points, while sales and marketing expense fell $4.9 million. Operating income improved, and the company returned to GAAP profitability.
- Results included a $15.3 million gain from lower contingent consideration estimates, chiefly reflecting reduced AngioVac sales projections and discontinued TiLo milestones. FY2017 also included a $12.5 million legal accrual and a $4.5 million pretax impact from the Acculis recall.
- FY2016’s large net loss included a $40.4 million U.S. deferred-tax valuation allowance; FY2017 tax expense was $4.8 million, with a 49% effective tax rate.
Outlook, commentary and material risks
- Management presented a three-year plan in April 2017 with targets for revenue, adjusted EPS, adjusted EBITDAS, free cash flow, adjusted gross margin and leverage. The filing text does not provide clear target values.
- The company planned to consolidate manufacturing from Manchester, Georgia and Denmead, U.K. into two New York facilities, targeting completion in FY2018’s third quarter. Estimated total costs were $6.25 million to $7.75 million; $1.3 million was recorded in FY2017.
- AngioDynamics recalled Acculis probes, withdrew the related capital systems and discontinued the product. The filing cites revenue deferral and inventory/hardware reserves, and says additional withdrawal costs were expected in FY2018.
- In August 2017, after year-end, the company agreed in principle to resolve DOJ investigations involving LC Beads and alleged promotion of certain VenaCure EVLT products for approximately $12.5 million, matching the FY2017 accrual.
- Pending Bard patent litigation concerns implantable ports; the company also filed an antitrust action against Bard relating to PICCs. The company had not accrued for potential losses in the patent cases because loss was not considered probable and reasonably estimable.
- Key risks include pricing and reimbursement pressure, competition and product adoption, FDA and other regulatory requirements, product liability and recalls, reliance on international distributors and limited-source suppliers, foreign exchange exposure, and execution of the facility consolidation. Debt carries floating interest rates.
- The board authorized up to $25 million of share repurchases through November 2018; $13.6 million was spent in FY2017. The company did not pay dividends and did not anticipate doing so in the foreseeable future.
Investor verification points
- Review the three-year plan’s actual targets and subsequent performance; target values are not clear in this filing text.
- Confirm the final DOJ settlement terms and any payments or additional costs beyond the $12.5 million accrual.
- Track Acculis withdrawal costs, product discontinuation effects and the FY2018 facility-consolidation timetable and savings.
- Assess whether the contingent-consideration gains reflect durable operating improvement: AngioVac projections were reduced, and BioFlo growth partly offset declines in other product lines.
- Monitor cash generation, working-capital movements, floating-rate debt, covenant headroom and the ability to fund operations and planned investment.
- Follow Bard litigation developments and any changes to the company’s assessment of potential exposure.